Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 17/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 17/20 | 0.63 |
| ▸ | NPC1 | O15118 | 1/20 | 0.60 |
| ▸ | ATM | Q13315 | 2/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11923150 | 0.85 | KMT2A (0.52) | MEN1KMT2ANPC1ATMHTT | |
| SCHEMBL20711471 | 0.84 | MEN1 (0.50) | MEN1KMT2ANPC1ATM | |
| SCHEMBL22299557 | 0.84 | KMT2A (0.49) | MEN1KMT2ANPC1ATMNPSR1 | |
| SCHEMBL13007693 | 0.82 | MEN1 (0.47) | MEN1KMT2ANPC1ATM | |
| SCHEMBL16233184 | 0.79 | ALDH1A1 (0.56) | MEN1KMT2ANPC1HTT | |
| SCHEMBL16572388 | 0.78 | ALDH1A1 (0.68) | MEN1KMT2ANPC1 | |
| SCHEMBL5510459 | 0.78 | ALDH1A1 (0.68) | MEN1KMT2ANPC1 | |
| SCHEMBL12791127 | 0.77 | MEN1 (0.51) | MEN1KMT2ANPC1NPSR1HTT | |
| SCHEMBL469061 | 0.76 | MEN1 (0.51) | MEN1KMT2ANPC1HTT | |
| SCHEMBL13271140 | 0.76 | MEN1 (0.50) | MEN1KMT2ANPC1ATMNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110178066-A1 | Hydroxypiperidine derivatives and uses thereof | AVALON PHARMACEUTICALS | 2011-07-21 | — | — | US | disclosed |
| US-20100249111-A1 | MULTI-RING COMPOUNDS AND USES THEREOF | AVALON PHARMACEUTICALS (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100249111-A1 | MULTI-RING COMPOUNDS AND USES THEREOF | AVALON PHARMACEUTICALS (US) | 2010-09-30 | — | — | US | disclosed |
| US-20090036429-A1 | Hydroxypiperidine Derivatives and Uses Thereof | AVALON PHARMACEUTICALS | 2009-02-05 | — | — | US | disclosed |
| US-20090036429-A1 | Hydroxypiperidine Derivatives and Uses Thereof | AVALON PHARMACEUTICALS | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249111-A1 | MULTI-RING COMPOUNDS AND USES THEREOF | TP53, BCOR, HPGDS | MEN1 3570/4885KMT2A 1723/4885NPC1 4111/4885 |
| US-20110178066-A1 | Hydroxypiperidine derivatives and uses thereof | HPGDS, HPGD, DPYD | MEN1 3974/4885KMT2A 2446/4885NPC1 4013/4885 |
| US-20090036429-A1 | Hydroxypiperidine Derivatives and Uses Thereof | HPGDS, HPGD, DPYD | MEN1 3974/4885KMT2A 2446/4885NPC1 4013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.